NCT04917679 is a Phase 2 clinical trial of Eltrombopag plus diacerein in Thrombocytopenia, sponsored by Qilu Hospital of Shandong University.

Who is sponsoring NCT04917679?

NCT04917679 is sponsored by Qilu Hospital of Shandong University.

What drugs are being tested in NCT04917679?

Interventions in NCT04917679: Eltrombopag plus diacerein, Eltrombopag.

What condition does NCT04917679 study?

NCT04917679 studies Thrombocytopenia.

Is NCT04917679 still recruiting?

NCT04917679 is currently completed. Last updated 19 October 2023.

Last reviewed 2023-10-19 · How we verify

NCT04917679

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Completed Phase 2 Last updated 19 October 2023

What this trial tests

Phase 2 trial testing Eltrombopag plus diacerein in Thrombocytopenia in 102 participants. Completed in 1 June 2022.

Timeline

1 September 2020

Primary endpoint
1 December 2021

1 June 2022

Quick facts

Lead sponsor	Qilu Hospital of Shandong University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	102
Start date	1 September 2020
Primary completion	1 December 2021
Estimated completion	1 June 2022
Sites	1 location across China

Drugs / interventions tested

Eltrombopag plus diacerein — full drug profile →
Eltrombopag (ELTROMBOPAG) — full drug profile →

Conditions studied

Thrombocytopenia — all drugs for Thrombocytopenia →

Sponsor

Qilu Hospital of Shandong University

Who can join

18 and older, any sex, with Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with low platelet count. As the first choice of the second-line treatment of ITP, thrombopoietin receptor agonist (TPO-RA) enable long-term remission in 50% to 60% of cases. However, about half of patients have no response or loss of response to eltrombopag due to unknown reasons, which can't be effectively improved by increasing the drug dose. Diacerein is an anthraquinone derivative used to treat joint diseases such as osteoarthritis. We speculate that the addition of diacerein to eltrombopag may offer sensitizer effect and maximize efficacy, which warrants further prospective studies to evaluate the efficacy and safety of the combination therapy as salvage strategy in ameliorating immune thrombocytopenia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial.
Sun L, Huang X, Wang J, Yuan C, et al · · 2024 · cited 5× · PMID 38958479 · DOI 10.1182/blood.2024025067
Advances in Drug Delivery Science for Diacerein: Strategies to Enhance Solubility, Bioavailability, and Pharmacokinetic Performance.
Naseri M, Ghobakhlou S, Heidarizade N, Akbari ME, et al · · 2025 · PMID 41471053 · DOI 10.3390/pharmaceutics17121539

Verify or expand the search:

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04917679 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
Last refreshed: 19 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04917679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing